Juvenile Diabetes Research Foundation: Mission, Strategy, and Priorities

Insel, Richard A.; Deecher, Darlene C.; Brewer, Jeffrey

doi:10.2337/db11-1398

Cited by 16 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research into encapsulation devices started in the 1980's, and there are currently eleven companies working on developing the technology (14), as well as the recently created JDRF Encapsulation Consortium which aims to bring encapsulation therapies to clinical trials in diabetes (26,27). One of the more successful devices, which consists of a clinical grade alginate-polyornithine microcapsule system (28), has made its way to clinical trials.…”

Section: Whole Pancreas and Islet Transplantationmentioning

confidence: 99%

Recent Advances in Cell Replacement Therapies for the Treatment of Type 1 Diabetes

Cogger

Nostro

2015

Endocrinology

View full text Add to dashboard Cite

Exogenous insulin administration is currently the only treatment available to all type 1 diabetes patients, but it is not a cure. By helping to regulate circulating blood glucose levels, it has significantly improved life expectancy, but there are still long-term complications associated with the disease that may be preventable with a treatment strategy that can provide better glycemic control. Isolated islet (or whole pancreas) transplantation, xenotransplantation, and the transplant of human pluripotent stem cell-derived β-cells provide the potential to restore endogenous insulin production and reestablish normoglycemia. Here, we discuss the latest advances in these fields, including the use of encapsulation technology, as well as some of the hurdles that still need to be overcome for these alternative therapies to become mainstream and/or progress to clinical development.

show abstract

Section: Whole Pancreas and Islet Transplantationmentioning

confidence: 99%

Recent Advances in Cell Replacement Therapies for the Treatment of Type 1 Diabetes

Cogger

Nostro

2015

Endocrinology

View full text Add to dashboard Cite

show abstract

“…JDRF has prioritized a public health orientation to both primary and secondary type 1 diabetes prevention, representing prevention before and after the onset of b-cell autoimmunity respectively, with targeting of not only relatives of type 1 diabetes-affected individuals, but targeting the entire childhood population with either risk screening for secondary prevention or intervention without risk screening for primary prevention. [32][33][34][35] Regulatory authorities and payers need to be educated with respect to benefit/risk of preventive interventions in the at-risk setting and need to hear from individuals and families affected by type 1 diabetes and type 1 diabetes patient advocacy organizations. Academia, industry, regulatory authorities, payers, healthcare providers, patients and their families, and patient advocacy groups will need to work together more effectively to deliver on prevention of type 1 diabetes.…”

Section: To Perform Smaller Shorter Practical and An Increased Nummentioning

confidence: 99%

Delivering on George Eisenbarth's Visionary Pursuit of Understanding Pathogenesis and Prevention of Type 1 Diabetes

Insel

2013

Diabetes Technology & Therapeutics

Self Cite

View full text Add to dashboard Cite

George Eisenbarth's pioneering and visionary research has provided a critical foundation that will be built on in the years ahead as we progress toward prevention of type 1 diabetes. His almost 30-year old model that type 1 diabetes was a chronic and predictable autoimmune disease with multiple identifiable progressive stages with a potential for interventions to prevent progression to symptomatic diabetes has stood the test of time. To deliver on the Eisenbarth vision and his "unfinished journey," the field needs: (1) to improve detection of risk of type 1 diabetes, (2) to improve staging and prediction of progression, (3) to perform smaller, shorter, practical, and an increased number of prevention clinical trials, and (4) to increase awareness of the potential for risk detection, staging, and prevention of type 1 diabetes and benefit/risk of prevention.

show abstract

“…A novel therapeutic strategy that aims to target the common molecular processes that are altered in ER-stressed β-cells may therefore offer promise. Because preventing type 1 diabetes before β-cell function decreases below critical levels may prove to be less challenging than curing established type 1 diabetes ( 17 ), further studies on this topic are particularly important for the development of novel prevention, diagnostic, and therapeutic strategies for type 1 diabetes.…”

Section: Targeting Er Stress For Preventing β-Cell Dysfunction and Aumentioning

confidence: 99%

ER Stress as a Trigger for β-Cell Dysfunction and Autoimmunity in Type 1 Diabetes

O’Sullivan-Murphy

Urano

2012

Diabetes

View full text Add to dashboard Cite

Juvenile Diabetes Research Foundation: Mission, Strategy, and Priorities

Cited by 16 publications

References 22 publications

Recent Advances in Cell Replacement Therapies for the Treatment of Type 1 Diabetes

Recent Advances in Cell Replacement Therapies for the Treatment of Type 1 Diabetes

Delivering on George Eisenbarth's Visionary Pursuit of Understanding Pathogenesis and Prevention of Type 1 Diabetes

ER Stress as a Trigger for β-Cell Dysfunction and Autoimmunity in Type 1 Diabetes

Contact Info

Product

Resources

About